Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,402,858
  • Shares Outstanding, K 254,810
  • Annual Sales, $ 91,250 K
  • Annual Income, $ -349,000 K
  • 60-Month Beta 1.57
  • Price/Sales 26.56
  • Price/Cash Flow N/A
  • Price/Book 4.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.28
  • Number of Estimates 7
  • High Estimate -0.21
  • Low Estimate -0.37
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +31.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.26 +1.84%
on 11/21/19
10.84 -13.01%
on 12/04/19
-0.12 (-1.26%)
since 11/13/19
3-Month
7.11 +32.63%
on 10/02/19
10.84 -13.01%
on 12/04/19
-0.37 (-3.78%)
since 09/13/19
52-Week
7.11 +32.63%
on 10/02/19
14.61 -35.48%
on 04/08/19
-1.09 (-10.36%)
since 12/13/18

Most Recent Stories

More News
Why Is Amicus Therapeutics (FOLD) Up 6% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FOLD : 9.43 (-0.84%)
Amicus Therapeutics, Inc. (FOLD) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Amicus Therapeutics, Inc. (FOLD).

FOLD : 9.43 (-0.84%)
How to Find Cheap Buy-Ranked Stocks Trading Under $10

How to Find Cheap Buy-Ranked Stocks Trading Under $10

TNK : 21.86 (+3.45%)
NPTN : 8.11 (-1.34%)
KGC : 4.34 (-0.46%)
FOLD : 9.43 (-0.84%)
BE : 6.78 (+9.18%)
SmarTrend Watching for Potential Pullback in Shares of Amicus Therapeut After 1.77% Gain

Amicus Therapeut (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $9.66 to a high of $9.95. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of...

FOLD : 9.43 (-0.84%)
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat

Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

AGEN : 3.84 (+0.26%)
FOLD : 9.43 (-0.84%)
ALKS : 20.87 (-1.79%)
ANIK : 53.15 (-0.65%)
Company News For Nov 12, 2019

Companies In The News Are: QRTEA, FOLD, NKTR, WBA, KKR.

KKR : 29.15 (-0.38%)
FOLD : 9.43 (-0.84%)
NKTR : 21.27 (-2.39%)
WBA : 57.88 (-1.19%)
QRTEA : 8.17 (-5.22%)
Fibrogen Inc is Among the Companies in the Biotechnology Industry with the Best Relative Performance (FGEN , NVTA , FOLD , SRPT , CYTK )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

FOLD : 9.43 (-0.84%)
FGEN : 46.69 (-1.99%)
NVTA : 17.16 (+0.76%)
Tupperware, Qualcomm fall; Walgreens, SunPower rise

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:

TUP : 7.56 (-1.05%)
CARB : 22.94 (unch)
FOLD : 9.43 (-0.84%)
XRX : 36.84 (-0.75%)
Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25.00% and 1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 9.43 (-0.84%)
Amicus Therapeutics: 3Q Earnings Snapshot

CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Monday reported a loss of $61.8 million in its third quarter.

FOLD : 9.43 (-0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade FOLD with:

Business Summary

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in...

See More

Key Turning Points

2nd Resistance Point 9.74
1st Resistance Point 9.59
Last Price 9.43
1st Support Level 9.30
2nd Support Level 9.16

See More

52-Week High 14.61
Fibonacci 61.8% 11.75
Fibonacci 50% 10.86
Fibonacci 38.2% 9.98
Last Price 9.43
52-Week Low 7.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar